Ventilatory Strategy Based on Ultrasound Lung Morphology in Patients With Focal ARDS (LUVS)

ARDS is characterized by a diffuse, bilateral, extensive alveolar-interstitial infiltrate related to damage to the alveolar membrane.

Studies of lung morphology assessed by CT scan have shown 2 types of ARDS. When the loss of ventilation is posterior and caudal, and the pulmonary parenchyma is otherwise "healthy", ARDS is said to be focal. When the loss of ventilation is diffuse, associated with excess tissue affecting the entire lung parenchyma, ARDS is said to be non-focal or diffuse.

Only one recent multicenter study has evaluated whether individualized PEEP adjustment according to lung morphology (focal vs. non-focal) could improve ARDS survival outcomes compared with standard of care. Results for the primary endpoint, 90-day mortality, were negative. But lung morphology was misclassified on CT occurred 85 (21%) of 400 patients. In addition, per-protocol analysis in which misclassified patients were excluded showed that mortality was significantly lower in the personalized ventilation group than in the control group.

Lung ultrasound may be the ideal bedside imaging technique. The loss of pulmonary aeration and its variations induced by therapeutic maneuvers can be quantified by lung ultrasound. Lung ultrasound is a non-invasive, non-ionizing radiation method that can be easily used at the bedside.

APRV ventilation coupled with spontaneous breathing activity prevents atelectasis formation, recruits less ventilated areas, prevents mechanical ventilation-induced lung injury and improves lung compliance.

The hypothesis is that a "LUVS" ventilatory strategy composed of a bundle of measures all aiming at reopening the atelectatic pulmonary zones in focal ARDS (synergistic effect of spontaneous ventilation in APRV mode, early prone sessions, and adjustment of PEEP according to the patient's BMI), could decrease the number of days under mechanical ventilation, compared to protective ventilation with low tidal volume according to the current international recommendations

Study Overview

• Status: Recruiting
• Conditions: Focal Acute Respiratory Distress Syndrome
• Intervention / Treatment: Procedure: LUVS" ventilatory strategy composed of a bundle of measures; Procedure: Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)

• Study Type: Interventional
• Enrollment (Estimated): 84
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: BOUHEMAD Belaid; Phone Number: 03 80 29 30 79; Email: belaid.bouhemad@chu-dijon.fr

Study Locations

• France
  • Dijon, France, 21000
    • Recruiting
    • CHU Dijon Bourgogne
    • Contact: ABAGRI Sohel; Email: sohel.abagri@chu-dijon.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• person who has given oral consent or has been included in an emergency
• Older than 18 years
• On mechanical ventilation for less than 24 hours
• Diagnosis of ARDS for less than 24 hours. ARDS according to the Berlin classification: i.e. arterial oxygen pressure to inspired oxygen fraction ratio less than or equal to 300, with a PEEP greater than or equal to 5, presence of bilateral radiological infiltrates not fully explained by heart failure or volume overload
• Focal ARDS determined on pulmonary ultrasound

Exclusion Criteria:

• person who is not a beneficiary of national health insurance
• person who is subject to a legal measure of protection (curatorship, guardianship)
• pregnant or breastfeeding women
• minor
• Patient having benefited from an invasive mechanical ventilation of more than one week in the previous month;
• ARDS in the previous month;
• Chronic respiratory failure under NIV or long term oxygen;
• Severe acute asthma;
• Lobectomy;
• Pneumothorax;
• Pneumomediastinum;
• Pulmonary fibrosis;
• Morbid obesity with a BMI above 40 ;
• Cancer with metastasis;
• Bone marrow transplantation;
• Chemotherapy-induced neutropenia;
• Cirrhosis with a Child-Pugh score of C;
• Suspected or confirmed intracranial hypertension;
• Concurrent participation in another ARDS study;
• Extensive burns on the torso.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: control	Procedure: Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française); Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)
Experimental: interventional	Procedure: LUVS" ventilatory strategy composed of a bundle of measures; Ventilation in APRV mode early prone sessions, adjustment of positive expiratory pressure according to the patient's BMI and no curarization

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of days without invasive ventilation	28 days

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire Dijon

Study record dates

Study Major Dates

• Study Start (Actual): October 13, 2021
• Primary Completion (Estimated): July 1, 2028
• Study Completion (Estimated): July 1, 2028

Study Registration Dates

• First Submitted: July 8, 2021
• First Submitted That Met QC Criteria: July 8, 2021
• First Posted (Actual): July 19, 2021

Study Record Updates

• Last Update Posted (Estimated): November 25, 2025
• Last Update Submitted That Met QC Criteria: November 20, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Respiration Disorders; Lung Diseases; Infant, Newborn, Diseases; Lung Injury; Infant, Premature, Diseases; Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Acute Lung Injury
• Other Study ID Numbers: BOUHEMAD Abagri 2021

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No